Please ensure Javascript is enabled for purposes of website accessibility

Why BioXcel Therapeutics Stock Is Down Today

By Prosper Junior Bakiny – Aug 14, 2020 at 11:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were not impressed with the company's latest quarterly update.

What happened?

Shares of clinical-stage biotech BioXcel Therapeutics (BTAI -0.53%) are down by 9.9% as of 11:58 a.m. EDT on Friday, after the company released its second-quarter earnings report before the market opened.

So what

BioXcel doesn't have any products on the market at the moment, and the company does not generate any revenue. However, the drugmaker reported a net loss of $21.4 million -- or $1.06 on a per-share basis. On average, analysts were expecting BioXcel's net loss per share to come in at $0.75. BioXcel's earnings miss may be the reason why investors sold off shares following today's release of its quarterly update.

The company's bottom-line decline was caused by a significant increase in its operating expenses -- to $21.4 million during the second quarter, up from $8.6 million recorded during the prior-year quarter. BioXcel ended the quarter with $65.5 million in cash and cash equivalents.

Five downward-bound arrows on a blackboard

Image source: Getty Images.

Now what

BioXcel's updates regarding its pipeline candidates may be more important than its financial results. Most notably, the company is currently developing BXCL501, a sublingual thin film, as a treatment for acute agitation associated with psychiatric conditions such as schizophrenia and bipolar disorder. In July, BioXcel reported positive results from a phase 3 clinical trial for BXCL501, and the company plans on submitting a New Drug Application in early 2021. The biotech argues that there are over 13 million patients in the U.S. who experience acute agitation, and the current treatment options are ineffective.

This market could represent a billion-dollar opportunity for BioXcel, and given today's sell-off, now may be a good time for interested investors to buy shares of this biotech stock.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioXcel Therapeutics, Inc. Stock Quote
BioXcel Therapeutics, Inc.
$11.19 (-0.53%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.